Table 3.
Outcomes after transplant
| Outcomes after allo-SCT | ||||
|---|---|---|---|---|
| Entire cohort (n = 28) | AML/MDS (n = 23) | |||
| % | 95% CI | % | 95% CI | |
| Relapse risk | ||||
| 100 Days | 14% | 4–30 | 13% | 3–30 |
| 6 Months | 29% | 13–46 | 26% | 10–45 |
| 1 Year | 54% | 36–74 | 61% | 36–78 |
| Non-relapse mortality | ||||
| 100 Days | 4% | 0–16 | 0% | |
| 6 Months | 7% | 1–21 | 4% | 0–19 |
| 1 Year | 18% | 6–34 | 13% | 3–30 |
| PFS | ||||
| 100 Days | 82% | 62–92 | 87% | 65–96 |
| 6 Months | 64% | 44–79 | 70% | 47–84 |
| 1 Year | 25% | 11–42 | 26% | 11–45 |
| OS | ||||
| 100 Days | 89% | 70–96 | 96% | 79–99 |
| 6 Months | 71% | 51–85 | 78% | 55–90 |
| 1 Year | 46% | 28–63 | 52% | 31–70 |
Abbreviations: CI = confidence interval; MDS = myelodysplastic syndrome.